moa glp 1 agonist Frontiers A Comprehensive Review of the
Description
After removing 420 duplicates and excluding 23 articles prior to screening, 1,509 records remained for title and abstract review
Diabetologia 66 (10), 17651779 (2023) B
Lancet 2008
These findings are consistent with data accessed on April 24, 2025
The exendin 939 concentration used in this experiment was approximately 30 times higher than its IC 50 value for CAP-induced TRPV1 activation, indicating the mode-selective characteristics of exendin 939
